Close Menu

NEW YORK (GenomeWeb) – UK-based Genedrive announced today that it has signed a conditional agreement with a firm called Epistem 2 to sell its contract research and pharmacogenomics divisions for a cash consideration of up to £1.9 million ($2.6 million), as part of a strategy to focus entirely on the molecular diagnostics market.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.